Thus, thefindings of an extensive study showed that EpCAM expression is detected in 48%of human breast cancer cases [95].Similarly to HER2, EpCAM is already employed as a target in monoclonalantibody-based immunotherapy (using Removab). This evidence concerns the gene EPCAM and breast carcinoma.